The Causes of Treatment Cessation in the Patients Suffering from Pulmonary Tuberculosis

Document Type : Research Paper


1 Associate Professor of Infectious Diseases Mashhad University of Medical Sciences, Mashhad, Iran

2 General Practitioner

3 Assistant of Infectious Diseases Mashhad University of Medical Sciences, Mashhad, Iran

4 Medical Student of University of Medical Sciences, Tehran, Iran


Recognizing factorsinvolved in the cessation and interruption of treatmenta disease like tuberculosis are important and can help us to improve the treatment strategy and educational status of the patients. 
Materials and MethodsDescriptive and retrospective study the case-sheets of all pulmonary tuberculosis' patients who were referred to the Mashhad Health Center No.2 during the years 2003 to 2005 were evaluated.
The total number of patients was 659. Of these patients, 534 (81%) were smear positive and 125 (19%) were smear negative pulmonary tuberculosis. Among the 534 smear-positive patients, 43 (8%) had treatment cessation or interruption. The reasons of treatment interruption were mortality due to T.B in 20 patients (3.7%), drug induced hepatitis in 11 (2%), premature sensation of well being in 2 (0.37%), hearing problems and vertigo in 2 (0.37%), multi drug resistance (MDR) tuberculosis in 2 (0.37%), purpura in 1 (0.2%), and exacerbation of renal failure in 2 (0.37%). However, 438 cases (82%) had been cured.
This syudy support the effectiveness of directly Observation supported the effectiveness of directly observed therapy short course (DOTS) strategy,Efforts to improve patients' understanding of TB disease and related treatment issues should be emphasized at the initiation of therapy .


1- Kaona FA, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment adherence and
knowledge of TB transmission among patients on TB treatment. BMC Public Health 2004; 4:68.
2- Driver C, Matus SP, Bayuga S, Winters AI, Munsiff SS. Factors associated with tuberculosis treatment interruption
in New York City. J Public Health Manag Pract 2005; 11:361-368.
3- onnolly C, Davies GR ,Wilkinson D.Who fails to complete tuberculosis treatment? Temporal trends and risk factors
for treatment interruption in a community-based directly observed therapy programme in a rural district of South
Africa. Int J Tuberc Lung Dis 1999; 3:1081-1087.
4- Marsh D, Hashim R, Hassany F, Hussain N, Iqbal Z, Irfanullah A, et al. Front-line management of pulmonary
tuberculosis: an analysis of tuberculosis and treatment practices in urban Sindh, Pakistan. Tuber Lung Dis 1996; 77:86-92.
5- Alvarez G.Perceptions and practices related with tuberculosis and treatment compliance in Chiapas, Mexico. Salud
Publica Mex 2000; 42:520-528.
6- Dhingra VK, Rajpal S, Aggarwal N, Aggarwaln JK, Shadab K, Jain SK. Adverse drug reactions observed during
DOTS. J Commun Dis 2004; 36:251-259.
7- Breen A.Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection.
Thorax 2006; 61:791-794. Epub 2006 Jul 14